Evidence map›Paper›PMID 37984946›Full record

ArticleBMJ open2023

Association of antecedent statin use on 30-day, 60-day and 90-day mortality among Mississippi Medicaid beneficiaries diagnosed with COVID-19.

Yiran Rong, Swarnali Goswami, Omokhodion Eriakha, Sujith Ramachandran, John Bentley, Benjamin F Banahan, Terri Kirby, Dennis Smith, Eric Pittman, Kaustuv Bhattacharya

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Yiran RongDepartment of Pharmacy Administration, University of Mississippi School of Pharmacy, University, Mississippi, USA.ORCID 0000-0002-8571-3872
Swarnali GoswamiDepartment of Pharmacy Administration, University of Mississippi School of Pharmacy, University, Mississippi, USA.
Omokhodion EriakhaDepartment of Pharmacy Administration, University of Mississippi School of Pharmacy, University, Mississippi, USA.
Sujith RamachandranDepartment of Pharmacy Administration, University of Mississippi School of Pharmacy, University, Mississippi, USA.ORCID 0000-0002-8792-4307
John BentleyDepartment of Pharmacy Administration, University of Mississippi School of Pharmacy, University, Mississippi, USA.
Benjamin F BanahanDepartment of Pharmacy Administration, University of Mississippi School of Pharmacy, University, Mississippi, USA.
Terri KirbyMississippi Division of Medicaid, Office of the Governor, Jackson, Mississippi, USA.
Dennis SmithMississippi Division of Medicaid, Office of the Governor, Jackson, Mississippi, USA.
Eric PittmanDepartment of Pharmacy Administration, University of Mississippi School of Pharmacy, University, Mississippi, USA.
Kaustuv BhattacharyaDepartment of Pharmacy Administration, University of Mississippi School of Pharmacy, University, Mississippi, USA kbhattac@olemiss.edu.
University of Mississippi · USMississippi Division of Medicaid · USJohnson & Johnson (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo assess if the antecedent statin use was associated with all-cause death among COVID-19 patients enrolled in Medicaid.

designCohort study.

settingMississippi Medicaid population.

participantsThis study included 10 792 Mississippi Medicaid-enrolled patients between 18 and 64 years of age with a confirmed COVID-19 diagnosis from March 2020 to June 2021.

interventionAntecedent statin use, which was determined by a record of statin prescription in the 90-day period prior to the COVID diagnosis.

main outcome measuresThe outcomes of interest included mortality from all cause within 30 days, 60 days and 90 days after index.

resultsA total of 10 792 patients with COVID-19 met the inclusion and exclusion criteria, with 13.1% of them being antecedent statin users. Statin users were matched 1:1 with non-users based on age, sex, race, comorbidities and medication use by propensity score matching. In total, the matched cohort consisted of 1107 beneficiaries in each group. Multivariable logistic regression showed that statin users were less likely to die within 30 days (adjusted OR: 0.51, 95% CI: 0.32 to 0.83), 60 days (OR: 0.56, 95% CI: 0.37 to 0.85) and 90 days (OR: 0.55, 95% CI: 0.37 to 0.82) after diagnosis of COVID-19. Those with low-intensity/moderate-intensity statin use had significantly lower mortality risk in the 60-day and the 90-day follow-up period, while the high intensity of statin use was only found to be significantly associated with a lower odd of mortality within 30 days post index.

conclusionAfter COVID infection, Medicaid beneficiaries who had taken statins antecedently could be at lower risk for death. For patients with chronic conditions, continuity of care is crucial when interruptions occur in their medical care. Further research is required to further investigate the potential mechanisms and optimal use of statins in COVID-19 treatment.

Indexed as

COVID-19Hydroxymethylglutaryl-CoA Reductase InhibitorsAdolescentAdultCohort StudiesCOVID-19 Drug TreatmentCOVID-19 TestingFemaleHumansMaleMedicaidMiddle AgedMississippiYoung AdultHydroxymethylglutaryl-CoA Reductase Inhibitorschronic diseaseCOVID-19lipid disordersmortalityretrospective studies

Identifiers

PMID37984946
PMCPMC10660820
OpenAlexW4388835456

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.